Corvus Pharmaceuticals Stock Alpha and Beta Analysis
| CRVS Stock | USD 5.01 0.28 5.92% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Corvus Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Corvus Pharmaceuticals over a specified time horizon. Remember, high Corvus Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Corvus Pharmaceuticals' market risk premium analysis include:
Beta 0.67 | Alpha (0.25) | Risk 6.46 | Sharpe Ratio (0.07) | Expected Return (0.42) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Corvus |
Corvus Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Corvus Pharmaceuticals market risk premium is the additional return an investor will receive from holding Corvus Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Corvus Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Corvus Pharmaceuticals' performance over market.| α | -0.25 | β | 0.67 |
Corvus Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Corvus Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Corvus Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Corvus Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Corvus Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Corvus Pharmaceuticals shares will generate the highest return on investment. By understating and applying Corvus Pharmaceuticals stock market price indicators, traders can identify Corvus Pharmaceuticals position entry and exit signals to maximize returns.
Corvus Pharmaceuticals Return and Market Media
The median price of Corvus Pharmaceuticals for the period between Sun, Oct 20, 2024 and Sat, Jan 18, 2025 is 8.03 with a coefficient of variation of 21.25. The daily time series for the period is distributed with a sample standard deviation of 1.56, arithmetic mean of 7.36, and mean deviation of 1.36. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Corvus Pharmaceuticals Sets New 52-Week High Should You Buy | 10/22/2024 |
2 | Corvus Pharmaceuticals, Inc. Q3 2024 Earnings Call Transcript | 11/13/2024 |
3 | Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis | 11/14/2024 |
4 | Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approac... | 12/04/2024 |
5 | Individual investors account for 50 percent of Corvus Pharmaceuticals, Inc.s ownership, while private equity firms account for 16 | 12/11/2024 |
6 | SP On Pace For 58th Record High Of The Year With Fed Set To Cut Rates | 12/18/2024 |
7 | Acquisition by Miller Richard A Md of 5000 shares of Corvus Pharmaceuticals at 1.59 subject to Rule 16b-3 | 12/20/2024 |
8 | Acquisition by Leiv Lea of 200000 shares of Corvus Pharmaceuticals at 1.64 subject to Rule 16b-3 | 01/02/2025 |
9 | Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference | 01/07/2025 |
10 | Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical ... | 01/13/2025 |
About Corvus Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Corvus or other stocks. Alpha measures the amount that position in Corvus Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Corvus Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Corvus Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Corvus Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Corvus Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Corvus Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Corvus Pharmaceuticals' management manipulating its earnings.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Corvus Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.